Breakthrough CD7 CAR-T Cell Therapy Shows Promise for T-ALL Patients
The National University Health System in Singapore has announced groundbreaking results from a novel CAR-T cell therapy targeting CD7, offering new hope for patients with relapsed or refractory T-cell acute lymphoblastic leukaemia (T-ALL). This innovative treatment, developed in partnership with the National University of Singapore, modifies patients’ T cells to enhance immune responses against cancer cells, showing promising outcomes in clinical trials. With the potential to improve survival rates and quality of life, this therapy represents a significant advancement in precision medicine for aggressive leukaemia.
Mother calls for more research into childhood leukaemia treatments
Tajana, the mother of a young leukaemia patient, is advocating for more research into less gruelling treatments for children with the blood cancer. Her son Henry, 13, is in remission after three years of chemotherapy. Tajana and Leukaemia UK are calling for more investment in treatments that work more quickly and take less of a physical toll on the children undergoing them.